IP Library Granted Patent US 8,394,587
Granted Patent B2
US 8,394,587 · App. 12/386,106 · Granted Mar 12, 2013

Single nucleotide polymorphisms and use of same predicting male-specific prenatal loss

Inventors: Mehmet Tevfik Dorak (Hamilton, NJ); Esma Ucisik-Akkaya (Selden, NY); Charronne Davis (Mahwah, NJ); Thuy Ngoc Do (Hamilton, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,587
App. No.
12/386,106
Granted
Mar 12, 2013
Kind
B2
Abstract

The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific prenatal loss of a conceptus or embryo. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk of prenatal loss is also disclosed.

Claims (28)

1. A method for predicting prenatal loss of a male conceptus or embryo, comprising the steps of:

(a) providing a biological sample from a pregnant woman;

(b) isolating a nucleic acid from said biological sample;

(c) performing a polymerase chain reaction (PCR) on said isolated nucleic acid to produce an amplicon;

(d) assessing said amplicon for the presence of adenine (A) at SNP GTF2H4 rs3909130; and

(e) predicting an increased risk of prenatal loss of said male conceptus or embryo in said pregnant woman by said presence of adenine (A) at said SNP GTF2H4 rs3909130,

wherein the presence of said adenine (A) at said SNP GTF2H4 rs3909130 is indicative of an increased risk of prenatal loss of said male conceptus or embryo.

2. The method of claim 1 , wherein said biological sample is derived from a conceptus or amniocentesis.

3. The method of claim 1 , wherein said nucleic acid is selected from the group consisting of genomic DNA, and isolated DNA.

4. The method of claim 1 , wherein said assessing step is performed by polymerase chain reaction-restriction fragment length polymorphism assay or TaqMan allelic discrimination assay.

5. The method of claim 4 , wherein said assessing step is performed by polymerase chain reaction-restriction fragment length polymorphism assay.

6. The method of claim 4 , wherein said assessing step is performed by TaqMan allelic discrimination assay.

7. The method of claim 1 , wherein said assessing step is performed by a process which comprises subjecting said isolated nucleic acid to a PCR flanking the region of said SNP.

8. The method of claim 1 , wherein said assessing step is performed on the presence of a SNP further selected from the group consisting of RXRB rs421446, BRD2 rs635688, HLA-E rs1264456, IRF4 rs12203592, IRF4 rs872071, LIF rs929271, TP53 rs1042522, MDM2 rs2279744, SLC11A2 rs422982, SLC40A1 rs1439814, and RRM2 rs1130609.

9. A method of predicting prenatal survival probability of a prospective male offspring of a couple, comprising the steps of:

(a) providing a biological sample from a pregnant woman;

(b) isolating nucleic acid from said biological sample;

(c) performing a polymerase chain reaction (PCR) on said isolated nucleic acid to produce an amplicon;

(d) assessing said amplicon for the presence of adenine (A) at SNP GTF2H4 rs3909130; and

(e) predicting a decreased prenatal survival probability of said prospective male offspring of said couple by said presence of adenine (A) at said SNP GTF2H4 rs3909130,

wherein the presence of said adenine (A) at said SNP GTF2H4 rs3909130 is indicative of a decreased prenatal survival probability of said prospective male offspring.

10. The method of claim 9 , wherein said assessing step is performed on the presence of a SNP further selected from the group consisting of RXRB rs421446, BRD2 rs635688, HLA-E rs1264456, IRF4 rs12203592, IRF4 rs872071, LIF rs929271, TP53 rs1042522, MDM2 rs2279744, SLC11A2 rs422982, SLC40A1 rs1439814, and RRM2 rs1130609.

11. The method of claim 9 , wherein said biological sample is derived from a conceptus or amniocentesis.

12. The method of claim 9 , wherein said nucleic acid is selected from the group consisting of genomic DNA, and isolated DNA.

13. The method of claim 9 , wherein said assessing step is performed by polymerase chain reaction-restriction fragment length polymorphism assay or TaqMan allelic discrimination assay.

14. The method of claim 9 , wherein said assessing step is performed by polymerase chain reaction-restriction fragment length polymorphism assay.

15. The method of claim 9 , wherein said assessing step is performed by TaqMan allelic discrimination assay.

16. The method of claim 9 , wherein said assessing step is performed by a process which comprises subjecting said isolated nucleic acid to a PCR flanking the region of said SNP.

Assignments (5)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2009
From: DORAK, MEHMET TEVFIK; UCISIK-AKKAYA, ESMA; DAVIS, CHARRONNE; DO, THUY NGOC
To: MEDICAL DIAGNOSTIC LABORATORIES, LLC
Reel/Frame 023533/0055 →
Continuity (3)
Provisional Application 61124111 · Apr 14, 2008
Provisional Application 61132634 · Jun 20, 2008
Related Publication 20100081135A1 · Apr 1, 2010